Gad Thomas has filed 34 insider transactions across 1 company since January 2024.
Most recent transaction: a disposition of 16000 shares of Y-mAbs Therapeutics, Inc. ($YMAB) on September 16, 2025.
Activity breakdown: 0 open-market purchases and 8 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Restricted Stock Units | 16000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.04% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Common Stock | 60235 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.13% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | U | Common Stock | 67681 | $8.60 | 0.0000 | 45,318,028 | 100.00% | 0.15% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | U | Common Stock | 60000 | $8.60 | 0.0000 | 45,318,028 | 100.00% | 0.13% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 143169 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.32% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 16000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.04% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 100000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.22% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 107500 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.24% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 130000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.29% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 91450 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.20% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 110000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.24% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 60000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.13% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 242200 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.53% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 75000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.17% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 132500 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.29% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Employee Stock Option (right to buy) | 64000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.14% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | D | Restricted Stock Units | 16000 | $0.00 | 0.0000 | 45,318,028 | 100.00% | 0.04% |
| Sept. 16, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | U | Common Stock | 245486 | $8.60 | 0.0000 | 45,318,028 | 100.00% | 0.54% |
| June 3, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | M | Employee Stock Option (right to buy) | 103000 | $0.00 | 0.0000 | 45,104,476 | 100.00% | 0.23% |
| June 3, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | M | Common Stock | 103000 | $2.00 | 433,402.0000 | 45,104,476 | 31.17% | 0.23% |
| March 7, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 10810 | $5.23 | 330,402.0000 | 44,328,962 | 3.17% | 0.02% |
| Jan. 17, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | A | Employee Stock Option (right to buy) | 64000 | $0.00 | 64,000.0000 | 44,328,962 | 9999.99% | 0.14% |
| Jan. 17, 2025 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | A | Common Stock | 32000 | $0.00 | 341,212.0000 | 44,328,962 | 10.35% | 0.07% |
| Sept. 19, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | M | Employee Stock Option (right to buy) | 22831 | $0.00 | 143,169.0000 | 44,022,356 | 13.75% | 0.05% |
| Sept. 19, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | M | Common Stock | 22831 | $4.38 | 309,212.0000 | 44,022,356 | 7.97% | 0.05% |
| Sept. 16, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 30000 | $12.97 | 286,381.0000 | 44,022,356 | 9.48% | 0.07% |
| Sept. 13, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 65000 | $13.47 | 316,381.0000 | 44,022,356 | 17.04% | 0.15% |
| June 10, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 35000 | $12.03 | 416,381.0000 | 43,779,456 | 7.75% | 0.08% |
| June 11, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 35000 | $12.00 | 381,381.0000 | 43,779,456 | 8.41% | 0.08% |
| May 21, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 25000 | $12.00 | 458,732.0000 | 43,779,456 | 5.17% | 0.06% |
| May 23, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 7351 | $13.00 | 451,381.0000 | 43,779,456 | 1.60% | 0.02% |
| March 5, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | S | Common Stock | 3900 | $16.44 | 483,732.0000 | 43,645,388 | 0.80% | 0.01% |
| Jan. 18, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | A | Employee Stock Option (right to buy) | 132500 | $0.00 | 132,500.0000 | 43,645,388 | 9999.99% | 0.30% |
| Jan. 18, 2024 | Y-mAbs Therapeutics, Inc. | $YMAB | Gad Thomas | CHIEF BUSINESS OFFICER | A | Common Stock | 22100 | $0.00 | 487,632.0000 | 43,645,388 | 4.75% | 0.05% |